Clinical review report : (Novo nordisk Canada Inc.). Insulin degludec and liraglutide injection (Xultophy) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Drug interactions.

Physical Description:

1 online resource (10 pages).

Edition:

Version: final (with redactions).

Place of Publication:

Ottawa (ON) : CADTH, 2019.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that insulin degludec and liraglutide (IDegLira) should be reimbursed as an adjunct to lifestyle modification, for the once-daily treatment of adults with T2DM to improve glycemic control in combination with metformin (MET), with or without sulfonylurea (SU), when these, combined with basal insulin (at doses of 20 to 50 units per day) do not provide adequate glycemic control, only if the following conditions are met : Conditions for Reimbursement. Discontinuation criteria: 1. IDegLira should be discontinued if the patient does not achieve a desirable level of glycemic control despite receiving a maximum dose of IDegLira (50 units of insulin degludec [IDeg] and 1.8 mg of liraglutide) after 26 weeks of treatment. Pricing condition: 1. Drug plan costs for IDegLira should not exceed the cost of the least costly glucagon-like peptide-1 receptor agonist (GLP-1 RA) plus the least costly basal insulin administered separately or in combination.

Notes:

Description based on publisher supplied metadata and other sources.